Omnicell’s Adjusted EPS of $0.58 Beats Estimates as Shares Rise 9.87%
Key Facts
Omnicell reported adjusted, non-GAAP earnings per share of $0.58 for the third quarter on October 29, 2026, versus an average estimate of $0.42, according to a Reuters report via Investing.com. The results were announced before the market opened, in line with the timing the company had previously set for its release. Revenue was $307.85 million, topping analysts’ estimate of $304.43 million. But revenue fell 1% year over year from $310.63 million in the third quarter of 2025. The results reflect improved adjusted profitability despite lower sales than in the year-earlier period.
Adjusted net income rose to $27 million in the third quarter of 2026, from $24 million in the same period a year earlier, according to Reuters. Adjusted earnings before interest, taxes, depreciation and amortization were $45 million, compared with $41 million in the third quarter of 2025. On a GAAP basis, the company recorded net income of $11 million, or $0.24 per diluted share. That compares with net income of $5 million, or $0.12 per share, in the third quarter of 2025. The figures put both adjusted performance and the accounting result on an upward year-over-year trajectory, while revenue remained below its prior-year level.
Chief Executive Randall Lipps said the company delivered "strong third-quarter results, and we continued to execute against our strategic priorities." He added that the discipline the company had built during the year and customer interest in solutions to improve efficiency, safety and productivity in medication management contributed to the results. Lipps said customers are evaluating the potential value of combining the XT platform with the OmniSphere cloud platform. According to his comments, these solutions aim to improve productivity, efficiency and workflow reliability. He also said the company sees a long-term opportunity in self-managed medication.
For its outlook, Omnicell expects adjusted earnings per share of $0.41 to $0.49 in the fourth quarter of 2026, with a midpoint of $0.45. That midpoint is above analysts’ estimate of $0.37. The company, meanwhile, set next-quarter revenue at $295 million to $301 million, with a midpoint of $298 million. That is below the consensus estimate of $310.4 million, putting the sales outlook below market expectations even as the midpoint of the earnings range exceeds them. The next-quarter guidance therefore presents a mixed picture, with earnings per share above consensus and expected revenue below it.
The company raised its adjusted earnings-per-share outlook for fiscal 2026 to $2.48 to $2.56, with a midpoint of $2.52, versus analysts’ expectations of $2.27. It also narrowed its annual revenue outlook to $1.225–$1.231 billion, with a midpoint of $1.228 billion. That midpoint compares with a consensus estimate of $1.23 billion, putting it slightly below. The previous annual revenue outlook ranged from $1.225 billion to $1.245 billion. Before the results, the company’s third-quarter revenue guidance was $301 million to $307 million, and it said it was raising both ranges for adjusted earnings before interest, taxes, depreciation and amortization and earnings per share while narrowing its annual revenue range.
Omnicell shares rose 9.87% in premarket trading on October 29 after the results were announced, according to a Reuters report via Investing.com. The stock had closed at $35.95 on October 28, according to L7 data. The initial market move followed the company’s third-quarter adjusted earnings-per-share and revenue beats. By contrast, the midpoint of fourth-quarter revenue guidance was below analyst consensus, while the midpoint of earnings-per-share guidance was above it. The company had announced that its earnings call would be held on October 29 at 8:30 a.m. Eastern Time.